Click for best price
Peptide Cancer Vaccine Market Size, Share 2023
| Market size in 2022 |
US$ 562.7 million
|
Forecast Market size by 2029 |
US$ 1895.9 million
|
| Growth Rate |
CAGR of 18.9% |
Number of Pages |
74 Pages |
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine. This report contains market size and forecasts of Peptide Cancer Vaccine in global, including the following market information:
Global Peptide Cancer Vaccine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Peptide Cancer Vaccine Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Peptide Cancer Vaccine companies in 2022 (%)
The global Peptide Cancer Vaccine market was valued at US$ 562.7 million in 2022 and is projected to reach US$ 1895.9 million by 2029, at a CAGR of 18.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
We surveyed the Peptide Cancer Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Peptide Cancer Vaccine Market, by Pipeline, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, by Pipeline, 2022 (%)
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Global Peptide Cancer Vaccine Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, by Application, 2022 (%)
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Global Peptide Cancer Vaccine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Peptide Cancer Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peptide Cancer Vaccine revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Peptide Cancer Vaccine revenues share in global market, 2022 (%)
Key companies Peptide Cancer Vaccine sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Peptide Cancer Vaccine sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Outline of Major Chapters:
Chapter 1: Introduces the definition of Peptide Cancer Vaccine, market overview.
Chapter 2: Global Peptide Cancer Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Peptide Cancer Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Peptide Cancer Vaccine Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 562.7 million
|
| Forecast Market size by 2029 |
US$ 1895.9 million
|
| Growth Rate |
CAGR of 18.9% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
74 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Peptide Cancer Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Pipeline
1.2.2 Market by Application
1.3 Global Peptide Cancer Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Peptide Cancer Vaccine Overall Market Size
2.1 Global Peptide Cancer Vaccine Market Size: 2022 VS 2029
2.2 Global Peptide Cancer Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Peptide Cancer Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Peptide Cancer Vaccine Players in Global Market
3.2 Top Global Peptide Cancer Vaccine Companies Ranked by Revenue
3.3 Global Peptide Cancer Vaccine Revenue by Companies
3.4 Global Peptide Cancer Vaccine Sales by Companies
3.5 Global Peptide Cancer Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Peptide Cancer Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Peptide Cancer Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Peptide Cancer Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Peptide Cancer Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Peptide Cancer Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Pipeline - Global Peptide Cancer Vaccine Market Size Markets, 2022 & 2029
4.1.2 ITK-1
4.1.3 GRN-1201
4.1.4 TPIV200
4.1.5 TPIV110
4.1.6 UV1
4.1.7 Galinpepimut-S
4.1.8 TARP 27-35
4.1.9 HER-Vaxx
4.1.10 Vx-001
4.1.11 Others
4.2 By Pipeline - Global Peptide Cancer Vaccine Revenue & Forecasts
4.2.1 By Pipeline - Global Peptide Cancer Vaccine Revenue, 2018-2023
4.2.2 By Pipeline - Global Peptide Cancer Vaccine Revenue, 2024-2029
4.2.3 By Pipeline - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
4.3 By Pipeline - Global Peptide Cancer Vaccine Sales & Forecasts
4.3.1 By Pipeline - Global Peptide Cancer Vaccine Sales, 2018-2023
4.3.2 By Pipeline - Global Peptide Cancer Vaccine Sales, 2024-2029
4.3.3 By Pipeline - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
4.4 By Pipeline - Global Peptide Cancer Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Peptide Cancer Vaccine Market Size, 2022 & 2029
5.1.2 Breast Cancer
5.1.3 Lung Cancer
5.1.4 Melanoma
5.1.5 Prostate Cancer
5.1.6 Others
5.2 By Application - Global Peptide Cancer Vaccine Revenue & Forecasts
5.2.1 By Application - Global Peptide Cancer Vaccine Revenue, 2018-2023
5.2.2 By Application - Global Peptide Cancer Vaccine Revenue, 2024-2029
5.2.3 By Application - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
5.3 By Application - Global Peptide Cancer Vaccine Sales & Forecasts
5.3.1 By Application - Global Peptide Cancer Vaccine Sales, 2018-2023
5.3.2 By Application - Global Peptide Cancer Vaccine Sales, 2024-2029
5.3.3 By Application - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
5.4 By Application - Global Peptide Cancer Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Peptide Cancer Vaccine Market Size, 2022 & 2029
6.2 By Region - Global Peptide Cancer Vaccine Revenue & Forecasts
6.2.1 By Region - Global Peptide Cancer Vaccine Revenue, 2018-2023
6.2.2 By Region - Global Peptide Cancer Vaccine Revenue, 2024-2029
6.2.3 By Region - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
6.3 By Region - Global Peptide Cancer Vaccine Sales & Forecasts
6.3.1 By Region - Global Peptide Cancer Vaccine Sales, 2018-2023
6.3.2 By Region - Global Peptide Cancer Vaccine Sales, 2024-2029
6.3.3 By Region - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Peptide Cancer Vaccine Revenue, 2018-2029
6.4.2 By Country - North America Peptide Cancer Vaccine Sales, 2018-2029
6.4.3 US Peptide Cancer Vaccine Market Size, 2018-2029
6.4.4 Canada Peptide Cancer Vaccine Market Size, 2018-2029
6.4.5 Mexico Peptide Cancer Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Peptide Cancer Vaccine Revenue, 2018-2029
6.5.2 By Country - Europe Peptide Cancer Vaccine Sales, 2018-2029
6.5.3 Germany Peptide Cancer Vaccine Market Size, 2018-2029
6.5.4 France Peptide Cancer Vaccine Market Size, 2018-2029
6.5.5 U.K. Peptide Cancer Vaccine Market Size, 2018-2029
6.5.6 Italy Peptide Cancer Vaccine Market Size, 2018-2029
6.5.7 Russia Peptide Cancer Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Peptide Cancer Vaccine Market Size, 2018-2029
6.5.9 Benelux Peptide Cancer Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Peptide Cancer Vaccine Revenue, 2018-2029
6.6.2 By Region - Asia Peptide Cancer Vaccine Sales, 2018-2029
6.6.3 China Peptide Cancer Vaccine Market Size, 2018-2029
6.6.4 Japan Peptide Cancer Vaccine Market Size, 2018-2029
6.6.5 South Korea Peptide Cancer Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Peptide Cancer Vaccine Market Size, 2018-2029
6.6.7 India Peptide Cancer Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Peptide Cancer Vaccine Revenue, 2018-2029
6.7.2 By Country - South America Peptide Cancer Vaccine Sales, 2018-2029
6.7.3 Brazil Peptide Cancer Vaccine Market Size, 2018-2029
6.7.4 Argentina Peptide Cancer Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Peptide Cancer Vaccine Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Peptide Cancer Vaccine Sales, 2018-2029
6.8.3 Turkey Peptide Cancer Vaccine Market Size, 2018-2029
6.8.4 Israel Peptide Cancer Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Peptide Cancer Vaccine Market Size, 2018-2029
6.8.6 UAE Peptide Cancer Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Boston Biomedical
7.1.1 Boston Biomedical Company Summary
7.1.2 Boston Biomedical Business Overview
7.1.3 Boston Biomedical Peptide Cancer Vaccine Major Product Offerings
7.1.4 Boston Biomedical Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Boston Biomedical Key News & Latest Developments
7.2 Ultimovacs
7.2.1 Ultimovacs Company Summary
7.2.2 Ultimovacs Business Overview
7.2.3 Ultimovacs Peptide Cancer Vaccine Major Product Offerings
7.2.4 Ultimovacs Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 Ultimovacs Key News & Latest Developments
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Company Summary
7.3.2 BrightPath Biotherapeutics Business Overview
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Major Product Offerings
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 BrightPath Biotherapeutics Key News & Latest Developments
7.4 TapImmune
7.4.1 TapImmune Company Summary
7.4.2 TapImmune Business Overview
7.4.3 TapImmune Peptide Cancer Vaccine Major Product Offerings
7.4.4 TapImmune Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.4.5 TapImmune Key News & Latest Developments
7.5 Immatics
7.5.1 Immatics Company Summary
7.5.2 Immatics Business Overview
7.5.3 Immatics Peptide Cancer Vaccine Major Product Offerings
7.5.4 Immatics Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.5.5 Immatics Key News & Latest Developments
7.6 Sellas
7.6.1 Sellas Company Summary
7.6.2 Sellas Business Overview
7.6.3 Sellas Peptide Cancer Vaccine Major Product Offerings
7.6.4 Sellas Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.6.5 Sellas Key News & Latest Developments
7.7 Imugene
7.7.1 Imugene Company Summary
7.7.2 Imugene Business Overview
7.7.3 Imugene Peptide Cancer Vaccine Major Product Offerings
7.7.4 Imugene Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.7.5 Imugene Key News & Latest Developments
7.8 VAXON Biotech
7.8.1 VAXON Biotech Company Summary
7.8.2 VAXON Biotech Business Overview
7.8.3 VAXON Biotech Peptide Cancer Vaccine Major Product Offerings
7.8.4 VAXON Biotech Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.8.5 VAXON Biotech Key News & Latest Developments
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Company Summary
7.9.2 Generex Biotechnology Business Overview
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Major Product Offerings
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.9.5 Generex Biotechnology Key News & Latest Developments
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Company Summary
7.10.2 ISA Pharmaceuticals Business Overview
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Major Product Offerings
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.10.5 ISA Pharmaceuticals Key News & Latest Developments
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Company Summary
7.11.2 OncoTherapy Science Peptide Cancer Vaccine Business Overview
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Major Product Offerings
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Sales and Revenue in Global (2018-2023)
7.11.5 OncoTherapy Science Key News & Latest Developments
8 Global Peptide Cancer Vaccine Production Capacity, Analysis
8.1 Global Peptide Cancer Vaccine Production Capacity, 2018-2029
8.2 Peptide Cancer Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Peptide Cancer Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Peptide Cancer Vaccine Supply Chain Analysis
10.1 Peptide Cancer Vaccine Industry Value Chain
10.2 Peptide Cancer Vaccine Upstream Market
10.3 Peptide Cancer Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Peptide Cancer Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Peptide Cancer Vaccine in Global Market
Table 2. Top Peptide Cancer Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Peptide Cancer Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Peptide Cancer Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global Peptide Cancer Vaccine Sales by Companies, (K Units), 2018-2023
Table 6. Global Peptide Cancer Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Peptide Cancer Vaccine Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Peptide Cancer Vaccine Product Type
Table 9. List of Global Tier 1 Peptide Cancer Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Peptide Cancer Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Pipeline ? Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Pipeline - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Pipeline - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Pipeline - Global Peptide Cancer Vaccine Sales (K Units), 2018-2023
Table 15. By Pipeline - Global Peptide Cancer Vaccine Sales (K Units), 2024-2029
Table 16. By Application ? Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Peptide Cancer Vaccine Sales (K Units), 2018-2023
Table 20. By Application - Global Peptide Cancer Vaccine Sales (K Units), 2024-2029
Table 21. By Region ? Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Peptide Cancer Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Peptide Cancer Vaccine Sales (K Units), 2018-2023
Table 25. By Region - Global Peptide Cancer Vaccine Sales (K Units), 2024-2029
Table 26. By Country - North America Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Peptide Cancer Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Peptide Cancer Vaccine Sales, (K Units), 2018-2023
Table 29. By Country - North America Peptide Cancer Vaccine Sales, (K Units), 2024-2029
Table 30. By Country - Europe Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Peptide Cancer Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Peptide Cancer Vaccine Sales, (K Units), 2018-2023
Table 33. By Country - Europe Peptide Cancer Vaccine Sales, (K Units), 2024-2029
Table 34. By Region - Asia Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Peptide Cancer Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Peptide Cancer Vaccine Sales, (K Units), 2018-2023
Table 37. By Region - Asia Peptide Cancer Vaccine Sales, (K Units), 2024-2029
Table 38. By Country - South America Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Peptide Cancer Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Peptide Cancer Vaccine Sales, (K Units), 2018-2023
Table 41. By Country - South America Peptide Cancer Vaccine Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Peptide Cancer Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Peptide Cancer Vaccine Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Peptide Cancer Vaccine Sales, (K Units), 2024-2029
Table 46. Boston Biomedical Company Summary
Table 47. Boston Biomedical Peptide Cancer Vaccine Product Offerings
Table 48. Boston Biomedical Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Boston Biomedical Key News & Latest Developments
Table 50. Ultimovacs Company Summary
Table 51. Ultimovacs Peptide Cancer Vaccine Product Offerings
Table 52. Ultimovacs Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Ultimovacs Key News & Latest Developments
Table 54. BrightPath Biotherapeutics Company Summary
Table 55. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Offerings
Table 56. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. BrightPath Biotherapeutics Key News & Latest Developments
Table 58. TapImmune Company Summary
Table 59. TapImmune Peptide Cancer Vaccine Product Offerings
Table 60. TapImmune Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. TapImmune Key News & Latest Developments
Table 62. Immatics Company Summary
Table 63. Immatics Peptide Cancer Vaccine Product Offerings
Table 64. Immatics Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Immatics Key News & Latest Developments
Table 66. Sellas Company Summary
Table 67. Sellas Peptide Cancer Vaccine Product Offerings
Table 68. Sellas Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Sellas Key News & Latest Developments
Table 70. Imugene Company Summary
Table 71. Imugene Peptide Cancer Vaccine Product Offerings
Table 72. Imugene Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Imugene Key News & Latest Developments
Table 74. VAXON Biotech Company Summary
Table 75. VAXON Biotech Peptide Cancer Vaccine Product Offerings
Table 76. VAXON Biotech Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. VAXON Biotech Key News & Latest Developments
Table 78. Generex Biotechnology Company Summary
Table 79. Generex Biotechnology Peptide Cancer Vaccine Product Offerings
Table 80. Generex Biotechnology Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Generex Biotechnology Key News & Latest Developments
Table 82. ISA Pharmaceuticals Company Summary
Table 83. ISA Pharmaceuticals Peptide Cancer Vaccine Product Offerings
Table 84. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. ISA Pharmaceuticals Key News & Latest Developments
Table 86. OncoTherapy Science Company Summary
Table 87. OncoTherapy Science Peptide Cancer Vaccine Product Offerings
Table 88. OncoTherapy Science Peptide Cancer Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. OncoTherapy Science Key News & Latest Developments
Table 90. Peptide Cancer Vaccine Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Peptide Cancer Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Peptide Cancer Vaccine Production by Region, 2018-2023 (K Units)
Table 93. Global Peptide Cancer Vaccine Production by Region, 2024-2029 (K Units)
Table 94. Peptide Cancer Vaccine Market Opportunities & Trends in Global Market
Table 95. Peptide Cancer Vaccine Market Drivers in Global Market
Table 96. Peptide Cancer Vaccine Market Restraints in Global Market
Table 97. Peptide Cancer Vaccine Raw Materials
Table 98. Peptide Cancer Vaccine Raw Materials Suppliers in Global Market
Table 99. Typical Peptide Cancer Vaccine Downstream
Table 100. Peptide Cancer Vaccine Downstream Clients in Global Market
Table 101. Peptide Cancer Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Peptide Cancer Vaccine Segment by Pipeline in 2022
Figure 2. Peptide Cancer Vaccine Segment by Application in 2022
Figure 3. Global Peptide Cancer Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Peptide Cancer Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Peptide Cancer Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. Peptide Cancer Vaccine Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2022
Figure 9. By Pipeline - Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Pipeline - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 11. By Pipeline - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 12. By Pipeline - Global Peptide Cancer Vaccine Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global Peptide Cancer Vaccine Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Peptide Cancer Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Peptide Cancer Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 23. US Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 28. Germany Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 37. China Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Peptide Cancer Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Peptide Cancer Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Peptide Cancer Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Peptide Cancer Vaccine Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Peptide Cancer Vaccine by Region, 2022 VS 2029
Figure 54. Peptide Cancer Vaccine Industry Value Chain
Figure 55. Marketing Channels
